Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register

British Journal of Dermatology

Volumn 173, Issue 2, 2015, Pages 510-518

  Iskandar, I Y K ^a   Ashcroft, D M ^a   Warren, R B ^b   Yiu, Z Z N ^b   McElhone, K ^b   Lunt, M ^b   Barker, J N W N ^c   Burden, A D ^d   Ormerod, A D ^e   Reynolds, N J ^f   Smith, C H ^c   Griffiths, C E M ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d WESTERN INFIRMARY   (United Kingdom)

^e UNIVERSITY OF ABERDEEN   (United Kingdom)

^f NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; CYCLOSPORIN A; ETANERCEPT; ETRETIN; FUMARIC ACID; HYDROXYUREA; INFLIXIMAB; METHOTREXATE; PSORALEN; USTEKINUMAB; BIOLOGICAL FACTOR; DERMATOLOGICAL AGENT;

ACTINIC KERATOSIS; ADULT; ANGINA PECTORIS; ANXIETY; ARTICLE; ASTHMA; BASAL CELL CARCINOMA; BODY MASS; BOWEN DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY FAILURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CORONARY ARTERY DISEASE; CROHN DISEASE; DEEP VEIN THROMBOSIS; DEMOGRAPHY; DEMYELINATING DISEASE; DEPRESSION; DERMATOLOGY LIFE QUALITY INDEX; DIABETES MELLITUS; DIGESTIVE SYSTEM INFLAMMATION; DISEASE DURATION; DISEASE SEVERITY; DYSLIPIDEMIA; EPILEPSY; ERYTHRODERMIC PSORIASIS; FEMALE; GUTTATE PSORIASIS; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEPATITIS; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; IRELAND; KERATOACANTHOMA; LONGITUDINAL STUDY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MELANOMA; MELANOMA SKIN CANCER; MIDDLE AGED; MULTICENTER STUDY; NON MELANOMA SKIN CANCER; OBESITY; OBSERVATIONAL STUDY; ONSET AGE; PEPTIC ULCER; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUSTULAR PSORIASIS; QUALITY OF LIFE; SKIN CARCINOMA; SYSTEMIC THERAPY; THYROID DISEASE; TUBERCULOSIS; ULCERATIVE COLITIS; ULTRAVIOLET A RADIATION; UNITED KINGDOM; ADOLESCENT; AGED; CLINICAL TRIAL; COMPLICATION; GREAT BRITAIN; PSORIASIS; REGISTER; YOUNG ADULT;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; BIOLOGICAL FACTORS; COMORBIDITY; DERMATOLOGIC AGENTS; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS; QUALITY OF LIFE; REGISTRIES; YOUNG ADULT;

EID: 84941172339     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13908     Document Type: Article

References (49)

1. Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM,. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377-85.
2. Gladman DD, Antoni C, Mease P, et al,. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64 (Suppl. 2): 14-17.
3. Samarasekera EJ, Neilson JM, Warren RB, et al,. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol 2013; 133: 2340-6.
4. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM,. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol 2010; 146: 891-5.
5. Fernandez-Torres RM, Paradela S, Fonseca E,. Psoriasis in patients older than 65 years. A comparative study with younger adult psoriatic patients. J Nutr Health Aging 2012; 16: 586-91.
6. Papp KA, Tyring S, Lahfa M, et al,. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152: 1304-12.
7. Gordon KB, Langley RG, Leonardi C, et al,. Clinical response to alimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55: 598-606.
8. Reich K, Nestle FO, Papp K, et al,. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-74.
9. Leonardi CL, Kimball AB, Papp KA, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-74.
10. National Institute for Health and Care Excellence. Psoriasis: the assessment and management of psoriasis. Clinical Guideline 153. Available at: http://www.nice.org.uk/guidance/CG153 (last accessed 28 June 2015).
11. Burden AD, Boon MH, Leman J, et al,. Diagnosis and management of psoriasis and psoriatic arthritis in adults: summary of SIGN guidance. Br Med J 2010; 341: c5623.
12. Schmitt-Egenolf M,. Psoriasis therapy in real life: the need for registries. Dermatology 2006; 213: 327-30.
13. Silman A, Symmons D, Scott DG, Griffiths I,. British Society for Rheumatology Biologics Register. Ann Rheum Dis 2003; 62 (Suppl. 2): 28-9.
14. Burden AD, Warren RB, Kleyn CE, et al,. The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives. Br J Dermatol 2012; 166: 545-54.
15. Smith CH, Anstey AV, Barker JNWN, et al,. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 987-1019.
16. Ibrahim G, Waxman R, Helliwell PS,. The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Care Res 2009; 61: 1373-8.
17. Catanoso M, Pipitone N, Salvarani C,. Epidemiology of psoriatic arthritis. Reumatismo 2012; 64: 66-70.
18. Rivera R, García-Doval I, Carretero G, et al,. [BIOBADADERM, the Spanish Registry of Adverse Events Associated with Biologic Drugs in Dermatology: first report]. Actas Dermosifiliogr 2011; 102: 132-41 (in Spanish).
19. Augustin M, Spehr C, Radtke MA, et al,. German psoriasis registry PsoBest: objectives, methodology and baseline data. J Deutsch Dermatol Ges 2014; 12: 48-58.
20. Menter A, Tyring SK, Gordon K, et al,. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-15.
21. Saurat JH, Stingl G, Dubertret L, et al,. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-66.
22. Gottlieb AB, Evans R, Li S, et al,. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51: 534-42.
23. Papp KA, Langley RG, Lebwohl M, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-84.
24. Kimball AB, Leonardi C, Stahle M, et al,. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). Br J Dermatol 2014; 171: 137-47.
25. Health & Social Care Information Centre. Statistics on obesity, physical activity and diet: England 2014. Available at: http://www.hscic.gov.uk/catalogue/PUB13648/Obes-phys-acti-diet-eng-2014-rep.pdf (last accessed 28 June 2015).
26. Sterry W, Strober BE, Menter A,. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007; 157: 649-55.
27. Henseler T, Christophers E,. Disease concomitance in psoriasis. J Am Acad Dermatol 1995; 32: 982-6.
28. Naldi L, Chatenoud L, Linder D, et al,. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125: 61-7.
29. Neimann AL, Shin DB, Wang X, et al,. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-35.
30. Herron MD, Hinckley M, Hoffman MS, et al,. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005; 141: 1527-34.
31. Puig L,. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol 2011; 25: 1007-11.
32. Naldi L, Addis A, Chimenti S, et al,. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Dermatology 2008; 217: 365-73.
33. Clark L, Lebwohl M,. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol 2008; 58: 443-6.
34. Aurangabadkar SJ,. Comorbidities in psoriasis. Indian J Dermatol Venereol Leprol 2013; 79 (Suppl. 7): S10-17.
35. Pouplard C, Brenaut E, Horreau C, et al,. Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. J Eur Acad Dermatol Venereol 2013; 27: 36-46.
36. Gelfand JM, Shin DB, Neimann AL, et al,. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 2006; 126: 2194-201.
37. Paul CF, Ho VC, McGeown C, et al,. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 2003; 120: 211-16.
38. Esposito M, Saraceno R, Giunta A, et al,. An Italian study on psoriasis and depression. Dermatology 2006; 212: 123-7.
39. NHS Information Centre for Health and Social Care. Adult psychiatric morbidity in England, 2007. Results of a household survey. Available at: http://www.hscic.gov.uk/catalogue/PUB02931/adul-psyc-morb-res-hou-sur-eng-2007-rep.pdf (last accessed 28 June 2015).
40. Langley RG, Feldman SR, Han C, et al,. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol 2010; 63: 457-65.
41. Menter A, Augustin M, Signorovitch J, et al,. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J Am Acad Dermatol 2010; 62: 812-18.
42. Tyring S, Gottlieb A, Papp K, et al,. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367: 29-35.
43. Feldman SR, Gottlieb AB, Bala M, et al,. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Br J Dermatol 2008; 159: 704-10.
44. Madanagobalane S, Anandan S,. The increased prevalence of non-alcoholic fatty liver disease in psoriatic patients: a study from South India. Australas J Dermatol 2012; 53: 190-7.
45. Miele L, Vallone S, Cefalo C, et al,. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51: 778-86.
46. van der Voort EAM, Koehler EM, Dowlatshahi EA, et al,. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: results from a population-based study. J Am Acad Dermatol 2014; 70: 517-24.
47. Bernstein CN, Wajda A, Blanchard JF,. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 2005; 129: 827-36.
48. Lees CW, Satsangi J,. Genetics of inflammatory bowel disease: implications for disease pathogenesis and natural history. Expert Rev Gastroenterol Hepatol 2009; 3: 513-34.
49. Cohen AD, Dreiher J, Birkenfeld S,. Psoriasis associated with ulcerative colitis and Crohn's disease. J Eur Acad Dermatol Venereol 2009; 23: 561-5.